Latest Breaking News On - Byisabella hornick - Page 2 : comparemela.com

Biologics lower exacerbations, hospitalizations in COPD, Th2 inflammation

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.“Because we took a real-world approach including all comers with COPD who received biologics, this may be more directly relatable to patients at large and

United statesStephenr dachertByisabella hornickKristen dowdTemple university hospitalAmerican thoracic society international conferenceAmerican thoracic society internationalAfrican american

Frequent extubation readiness assessments lower ICU length of stay

Frequent extubation readiness assessments lower ICU length of stay
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSan diego state universityKristen dowdByisabella hornickJulie kathryn grahamSan diego state university school of nursingAmerican thoracic society international conferenceSociety for critical care medicineAmerican thoracic society internationalKathryn grahamSan diego state university schoolCritical care medicine

24-week ensifentrine improves dyspnea in moderate to severe COPD

24-week ensifentrine improves dyspnea in moderate to severe COPD
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoVerona pharmaKristen dowdDonalda mahlerByisabella hornickDartmouth universityAmerican thoracic society international conferenceTransitional dyspnea indexAmerican thoracic society internationalValley regional hospitalTransition dyspnea index

Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.“Tezepelumab is a monoclonal antibody that specifically blocks [thymic stromal lymphopoietin] from interacting with its receptor,” Dave Singh,

United statesSan diegoRobert fogelByisabella hornickDave singhKristen dowdUniversity of manchesterAmerican thoracic society international conferenceAmerican thoracic society internationalRespiratory questionnaire

Educational texts raise physicians confidence in treating tobacco use disorder

SAN DIEGO — After receiving educational texts on tobacco use disorder treatment for 13 days, physicians felt more confident treating this disorder, according to research presented at the American Thoracic Society International Conference.This research was highlighted during the 2024 ATS-Association of Pulmonary and Critical Care Medicine Program Directors-Pediatric Pulmonary Training

United statesKristen dowdZehra dhananiByisabella hornickAmerican thoracic society international conferenceCritical care medicine program directorsTemple university hospitalAmerican thoracic society internationalClinical educators